Belova: A non-interventional study to collect data on the safety and efficacy of frontline bevacizumab treatment in Figo Stage IV Ovarian Cancer patients ≥ 70 (BELOVA)

Study identification

• EU PAS number:
  EUPAS13849
• Study ID:
  35793
• Official title and acronym:
  Belova: A non-interventional study to collect data on the safety and efficacy of frontline bevacizumab treatment in Figo Stage IV Ovarian Cancer patients ≥ 70 (BELOVA)
• DARWIN EU® study:
  No
• Study countries:
  Belgium
• Study description:
  This is a multi-center, non-interventional, post-authorization study to collect safety and efficacy data on the use of bevacizumab in ovarian cancer patients ≥ 70 years.Dosing and treatment duration are at the discretion of the investigator in accordance with the local labeling and reimbursement.Patients will be followed from start of bevacizumab treatment until progression or death from any cause, whichever comes first.The study will be open for recruitment for 3 years, then a follow-up period until the last patient has had disease progression or died, whichever comes first.
• Study status:
  Finalised

Research institutions and networks

Institutions

Multiple centres: 20 centres are involved in the study

Study timelines

Date when funding contract was signed

Actual:25/02/2014

Study start date

Actual:23/04/2015

Date of final study report

Actual:04/06/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Roche

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

ML29515